URSODEZOKSIHOLEVAJA ACID: THERAPIST’S VIEW

The article gives information on the scope of ursodeoxycholic acid (UDCA). The most evident positive effects of therapy for cholelithiasis (SCI) and in primary biliary cirrhosis (PBC). The probability of using UDCA as a means of preventing CLS in cases of biliary sludge (SB) and in the risk group in elderly and elderly people is discussed. The data of our own study of the results of UDCA in 34 patients with non-alcoholic fatty liver disease, combined with the dyskinesia of the gallbladder (BL), BS and gastroesophageal reflux disease (GERD) are presented. Admission UDCA Grinterol demonstrated high clinical efficacy, safety and the absence of side effects.